Liver fibrosis is a major global health concern, developing as a result of chronic liver diseases (CLDs) such as viral ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) ...

SINGAPORE: A new study from Duke-NUS Medical School has identified a promising new avenue for tackling pulmonary fibrosis, a ...

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...

UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.